Cooperativity of alpha-naphthoflavone in cytochrome P450 3A-dependent drug oxidation activities in hepatic and intestinal microsomes from mouse and human.
1. The effects of several CYP3A substrates (alpha-naphthoflavone (alphaNF), terfenadine, midazolam, erythromycin) on nifedipine oxidation and testosterone 6beta-hydroxylation activities were investigated in hepatic and intestinal microsomes from mouse and human. 2. alphaNF (10 microM) and terfenadine (100 microM) inhibited nifedipine oxidation activities (at substrate concentration of 100 microM) in mouse hepatic microsomes to approximately 50%, but not in mouse intestinal microsomes. alphaNF (30 microM) stimulated nifedipine oxidation activities in mouse and human intestinal microsomes and in human hepatic microsomes to approximately 1.3-1.8-fold. Inhibitory potencies (50% inhibition concentration, IC50) of midazolam and erythromycin for nifedipine oxidations were calculated to be approximately 90 microM in human intestinal microsomes. In contrast, testosterone (100 microM) stimulated the nifedipine oxidation activities approximately 1.5-fold in hepatic and intestinal microsomes from mouse and human. 3. alphaNF showed different effects on the kinetic parameters including the Hill coefficients of nifedipine oxidation and testosterone 6beta-hydroxylation catalysed by hepatic and intestinal microsomes from mouse and human. Cooperativity in nifedipine oxidation was increased by the addition of alphaNF to pooled human hepatic microsomes, but little effects of alphaNF could be observed in individual human intestinal microsomes. 4. These results suggest that CYP3A enzymes in liver and intestine might have different characteristics and that observations from hepatic microsomes should not be directly applicable to intestine metabolism in some cases. Studies of drug-drug interactions of CYP3A substrates are recommended to be performed using intestinal samples.
Emoto
C
C
Faculty of Pharmaceutical Sciences, Kanazawa University, Japan.
Yamazaki
H
H
Iketaki
H
H
Yamasaki
S
S
Satoh
T
T
Shimizu
R
R
Suzuki
S
S
Shimada
N
N
Nakajima
M
M
Yokoi
T
T
D000818:Animals; D001571:Benzoflavones / Q000494:pharmacology*; D002478:Cells, Cultured; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004917:Erythromycin / Q000494:pharmacology; D018757:GABA Modulators / Q000494:pharmacology; D005765:Gastrointestinal Agents / Q000494:pharmacology; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D006801:Humans; D020128:Inhibitory Concentration 50; D007422:Intestines / Q000187:drug effects / Q000201:enzymology*; D007700:Kinetics; D051379:Mice; D008861:Microsomes / Q000187:drug effects / Q000201:enzymology*; D008862:Microsomes, Liver / Q000187:drug effects / Q000201:enzymology*; D008874:Midazolam / Q000494:pharmacology; D006899:Mixed Function Oxygenases / Q000378:metabolism*; D009543:Nifedipine / Q000494:pharmacology; D010100:Oxygen / Q000378:metabolism*; D011485:Protein Binding; D013250:Steroid Hydroxylases / Q000378:metabolism; D016593:Terfenadine / Q000494:pharmacology; D013739:Testosterone / Q000494:pharmacology; D014665:Vasodilator Agents / Q000494:pharmacology
D001571:Benzoflavones; D004791:Enzyme Inhibitors; D018757:GABA Modulators; D005765:Gastrointestinal Agents; D006634:Histamine H1 Antagonists; D014665:Vasodilator Agents; D013739:Testosterone; C011512:alpha-naphthoflavone; D004917:Erythromycin; D016593:Terfenadine; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; D013250:Steroid Hydroxylases; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; C022657:steroid hormone 6-beta-hydroxylase; D009543:Nifedipine; D008874:Midazolam; D010100:Oxygen